Dendreon

Executive Summary

Dendreon is a commercial-stage biotechnology company and a pioneer in autologous cellular immunotherapy, best known for its flagship product Provenge (sipuleucel-T) for the treatment of metastatic castration-resistant prostate cancer. Founded in 1992 and headquartered in Seal Beach, California, the company has established itself as a leader in the development and commercialization of personalized cancer vaccines. In addition to its proprietary product, Dendreon operates a contract development and manufacturing organization (CDMO) that provides cell therapy manufacturing services to other developers, leveraging its expertise and facility to diversify revenue streams. Looking ahead, Dendreon's near-term focus centers on expanding the label for Provenge to earlier stages of prostate cancer and exploring combination therapies with immune checkpoint inhibitors to enhance efficacy. The CDMO business is also poised for growth as the cell therapy sector expands. While the company faces competition from next-generation immunotherapies, its validated manufacturing platform and commercial infrastructure provide a solid foundation. Key catalysts include potential FDA label expansion decisions, new CDMO partnership announcements, and clinical data readouts from combination trials, which could drive near-term value.

Upcoming Catalysts (preview)

• Q3 2026FDA decision on Provenge label expansion to early-stage prostate cancer60% success
• Q4 2026New CDMO partnership or contract win70% success
• Q1 2027Phase 3 combination trial results of Provenge with checkpoint inhibitor50% success